Monday , July 23 2018
Home / David L. Joffe, BSPharm, CDE, FACA (page 14)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA
(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

May 13, 2017

This week, the Giro d’Italia started. This professional bike race stretches from the island of Sicily to the Alps and covers 2,250 miles of pedaling over 21 days. This Sunday, the Amgen Tour of California, America’s premier cycling event, begins and Team Novo Nordisk joins with 16 other professional teams …

Read More »

May 9, 2017

We have spent the better part of the last two months delving deep into the subject of Glucose metabolism in our Clinical Text. As we come to nearly the close of the author’s focus on Glycolysis, take a look to see how there may be new targets for diabetes and …

Read More »

May 6, 2017

Diabetes research can be a very fickle world at times. Over the years we have heard of many “cures” for type 1 diabetes. Most of the time the discoverer is someone not well known in the diabetes community and the work is dismissed as pie in the sky. This kind …

Read More »

May 2, 2017

We all make the assumption that insulin resistance comes from eating too much glucose. However, for many patients, this resistance occurs because they release too much insulin. This can be environmentally related or it can be blamed on heredity. Regardless of the cause, this hyperinsulinemia can result in long-lasting effects …

Read More »

April 29, 2017

The first line therapy for type 2 diabetes has long been metformin, and nowadays we are using it for patents who have prediabetes; it is also used “unofficially” by a lot of Weight Loss clinics. A lot of patients who are on metformin progress to insulin, and for many years …

Read More »

April 25, 2017

We all know of patients who walk around with glucose levels of 400mg/dl without any problems functioning. Most of our patients are often 100-200 points too high and they don’t even know it. When we start them on insulin, we usually go slow for fear of hypoglycemia, as often it …

Read More »

April 22, 2017

For many years, we never really gave great concern to the micro- and macrovascular problems in type 2 patients. Most of them were not diagnosed until they were in their late 50’s or early 60’s, and they did not really live long enough to develop severe problems. Now that diabetes …

Read More »

April 18, 2017

I recently spent some time talking to the director of one of the transplant centers in Florida that specializes in liver and kidney transplants. She was explaining all the the factors that go into finding a correct match for patients, how patients who need a kidney are selected and how …

Read More »

April 15, 2017

This week, the AMA, in their journal, advised that they were in discussions to shift their focus from A1c and glucose readings as an indicator of successful diabetes management to a more cardiovascular outcomes and mortality data measurement of success. I am in total agreement that improving these numbers will …

Read More »

April 11, 2017

I got to the office in Atlanta after a week at home and it looked like the sidewalks have been coated with yellow paint. But it was pollen from all the trees. Evidently the rapid changes in temperature over the past month or so had driven the pollen factor into …

Read More »